A Phase 3 interventional study of GSK1349572 and Raltegravir in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 181 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-15.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.
Among the 55 studies testing dolutegravir in HIV Infections, this one is the 7th largest by enrollment, is one of 4 that started in 2010, is one of 21 in phase 3, and was the 7th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
ViiV Healthcare · Sites in United States
Ages 6–12
By country, each count listing its studies:
Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 24 · Phase 4 11
First in 2009; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 724 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 126 across the 55 interventional studies. Of the 43 that completed or were terminated, 26 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 10th largest by enrollment of the 210 interventional ones that give a count, is one of 9 that started in 2010, is one of 65 in phase 3, and was the 143rd registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing dolutegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing dolutegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected antiretroviral experienced, integrase-naïve subjects. Subjects will be randomized 1:1 to receive GSK1349572 50 mg once daily or raltegravir (RAL) 400 mg twice daily, each added to an investigator selected background regimen consisting of at least one fully active agent plus no more than one second single agent which may or may not be active. Antiviral activity, safety, pharmacokinetics (PK), and development of viral resistance will be evaluated.
ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected antiretroviral experienced, integrase-naïve subjects. Subjects will be randomized 1:1 to receive GSK1349572 50 mg once daily or raltegravir (RAL) 400 mg twice daily, each added to an investigator selected background regimen consisting of at least one fully active agent plus no more than one second single agent which may or may not be active. Antiviral activity, safety, pharmacokinetics (PK), and development of viral resistance will be evaluated.
Subjects must have documented genotypic or phenotypic resistance to at least one member of each of at least two antiretroviral therapy (ART) drug classes [nucleoside/nucleotide reverse transcriptase inhibitor (N[t]RTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), fusion inhibitor (T20), or entry inhibitor (chemokine receptor 5 [CCR5] antagonist)].
The primary analysis will take place after the last subject completes 48 weeks on therapy. An additional data cut and analysis will be conducted after the last subject completes 24 weeks on therapy.
Subjects randomized to GSK1349572 who successfully complete Week 48 will continue to received GSK1349572 until either it is locally available, until they no longer derive clinical benefit, until they meet a protocol-defined reason for discontinuation, or until development of the compound is terminated.
ViiV Healthcare is the sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
This study's enrollment of 724 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.
Drug: GSK1349572 · Drug: Raltegravir Placebo
Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.
Drug: Raltegravir · Drug: GSK1349572 Placebo
50mg once daily
400mg twice daily
Inactive placebo tablet once daily
Inactive placebo tablet twice daily
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48
The percentage of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<50 c/mL at Week 48 was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the randomized phase of the study.
Time frame: At Week 48
Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Integrase Inhibitor (INI) Resistance at Time of Protocol Defined Virology Failure (PDVF)
For par. meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure and Baseline were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) virologic non-response: a decrease in plasma HIV-1 RNA of \<1 logarithm to base 10 (log10) copies/mL by Week 16, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/ mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) virologic rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.Treatment-emergent IN mutations are those detected at the time of PDVF but not at Baseline.
Time frame: Baseline (Day 1) until PDVF (Up to Week 48)
Number of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
The number of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<50 c/mL at Week 24 was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at Week 24 as nonresponders, as well as participants who switched their concomitant ART prior to Week 24 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA measurement through Week 24 (within window) while the participant was on-treatment. The result below corresponds to the Week 24 interim analysis.
Time frame: At Week 24
Number of Participants With Plasma HIV-1 RNA <400 c/mL at Week 24 and Week 48
The number of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<400 c/mL at the visit of interest was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at the visit of interest as nonresponders, as well as participants who switched their concomitant ART prior to the visit of interest as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA measurment (within window) for the timepoint of interest while the participant was on-treatment.
Time frame: At Week 24 and Week 48
Absolute Values of Cluster of Differentiation 4+ (CD4+) Cell Counts at Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 96 and 144
Blood samples were collected at specified time points to assess CD4+ using flow cytometry. Median and interquartile range are presented. Baseline was the latest pre-dose assessment value (Day 1).
Time frame: Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 96 and 144
Change From Baseline in CD4+ Cell Counts at Weeks 4, 8, 12,16, 24, 32, 40, 48, 96 and 144
Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline was the latest pre-dose assessment value (Day 1). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Median and interquartile range is presented.
Time frame: Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 96 and 144
Number of Participants With Post-Baseline HIV-associated Conditions, Excluding Recurrences, and Disease Progressions
Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of following conditions (CON), without any CON listed in Categories B and C: Asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: Symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C:Clinical CON listed in acquired immunodeficiency syndrome (AIDS) surveillance case definition. Indicators of CDP defined as:CDC CAT A at Baseline (BS) to CDC CAT C event (EV); CDC CAT B at BS to CDC CAT C EV; CDC CAT C at BS to new CDC CAT C EV; or CDC CAT A, B, or C at BS to death.
Time frame: Up to Week 480
Number of Participants With Post-Baseline Emergent Grade 1 to 4 Clinical Chemistry and Hematology Toxicities
All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Higher the grade, more severe the symptoms.
Time frame: From Baseline (Day 1) until Week 48, including participants with post-treatment events occurring after Week 48 for participants not entering the post-Week 48 Open-Label phase of the study
Number of Participants With Post-Baseline Emergent Grade 1 to 4 Clinical Chemistry and Hematology Toxicities
Blood samples were collected for the analysis of clinical chemistry and hematology parameters: Alanine aminotransferase (ALT), albumin, alkaline phosphate (ALP), aspartate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hypoonatremia, LDL cholesterol, lipase, total bilirubin, triglycerides, hemoglibin, neutrophils, platelets, white blood cells. Any abnormality in clinical chemistry and hematology parameters were evaluated according to the DAIDS toxicity scale From Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).Higher the grade, more severe the symptoms.
Time frame: From Week 48 to Week 480
DTG PK Parameters Including Maximum Plasma Drug Concentration (Cmax), Minimal Plasma Drug Concentration (Cmin), and Average Plasma Pre-dose Concentration (C0_avg)
Cmax, Cmin and C0_avg were assessed by population pharmacokinetic (PK) modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48. Cmax, Cmin and C0_avg were estimated and reported here.
Time frame: Pre-dose and at 1 to 3 hours or 4 to 12 hours post-dose at Week 4; Pre-dose at Week 24; Pre-dose and 1 to 3 hours or 4 to 12 hours post-dose at Week 48
DTG PK Parameter Including Pre-dose Concentration (C0)
C0 was assessed by population PK modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48. DTG predose concentration (C0) at Week 4, Week 24, and Week 48 was estimated and reported here.
Time frame: Pre-dose at Weeks 4, 24 and 48
DTG PK Parameters Including Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau Over a Dosing Interval at Steady State (AUC[0-tau])
AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. AUC was assessed by population pharmacokinetic (PK) modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48.
Time frame: Pre-dose and at 1 to 3 hours or 4 to 12 hours post-dose at Week 4; Pre-dose at Week 24; Pre-dose and 1 to 3 hours or 4 to 12 hours post-dose at Week 48
Change From Baseline in European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L) Utility Score
The EQ-5D-3L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 3 levels for each dimension including 1=no problems, 2=some problems, 3=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-3L utility score ranges from -0.594 to 1. Higher scores indicate better health. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 24 and 48
Change From Baseline in European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L) Thermometer Scores
The EQ-5D-3L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 3 levels for each dimension including 1=no problems, 2=some problems, 3=extreme problems. EQ-5D-3L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Participants were asked to rate their current health status using the visual analogue scale 'Thermometer'. Score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better heath. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 24 and 48
Absolute Values of Cluster of Differentiation 8+ (CD8+) Cell Counts at Weeks 4, 8, 12, 16, 24, 32, 40, and 48
The absolute value data for CD8+ cell count was planned to be evaluated. The results for this outcome measure will never be posted.
Time frame: At Weeks 4, 8, 12, 16, 24, 32, 40, and 48
Change From Baseline in CD8+ Cell Counts at Weeks 4, 8, 12, 16, 24, 32, 40, and 48
Change from Baseline data for CD8+ cell count was planned to be evaluated. The results for this outcome measure will never be posted.
Time frame: Baseline (Day 1); Weeks 4, 8, 12, 16, 24, 32, 40, and 48
This study was conducted to demonstrate non-inferior antiviral activity of dolutegravir (DTG) 50 milligram (mg) once daily versus raltegravir (RAL) 400 mg twice daily in participants with human immunodeficiency viruses (HIV)-1. Long-term antiviral activity, tolerability \& safety were also evaluated
| Milestone | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Started | 360 | 364 |
| Itt-e population | 357 | 362 |
| Modified (m)itt-e population | 354 | 361 |
| Completed | 299 | 283 |
| Not completed | 61 | 81 |
| Withdrew: Adverse event | 4 | 11 |
| Withdrew: Lack of efficacy | 20 | 42 |
| Withdrew: Protocol violation | 9 | 6 |
| Withdrew: Met protocol-defined stopping criteria | 5 | 3 |
| Withdrew: Lost to follow-up | 5 | 10 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 11 | 5 |
| Withdrew: Site closed | 3 | 1 |
| Withdrew: Randomized, but did not receive treatment | 3 | 2 |
| Milestone | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Started | 295 | 126 |
| Completed | 227 | 109 |
| Not completed | 68 | 17 |
| Withdrew: Physician decision | 5 | 0 |
| Withdrew: Lack of efficacy | 27 | 11 |
| Withdrew: Protocol violation | 10 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 |
| Withdrew: Met protocol-defined stopping criteria | 2 | 0 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Lost to follow-up | 12 | 2 |
The percentage of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<50 c/mL at Week 48 was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the randomized phase of the study.
| Percentage of participants | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 | 71 | 64 |
For par. meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure and Baseline were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) virologic non-response: a decrease in plasma HIV-1 RNA of \<1 logarithm to base 10 (log10) copies/mL by Week 16, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/ mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) virologic rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.Treatment-emergent IN mutations are those detected at the time of PDVF but not at Baseline.
| Participants | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Integrase Inhibitor (INI) Resistance at Time of Protocol Defined Virology Failure (PDVF) | 4 | 17 |
The number of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<50 c/mL at Week 24 was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at Week 24 as nonresponders, as well as participants who switched their concomitant ART prior to Week 24 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA measurement through Week 24 (within window) while the participant was on-treatment. The result below corresponds to the Week 24 interim analysis.
| Participants | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Number of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24 | 281 | 252 |
The number of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<400 c/mL at the visit of interest was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at the visit of interest as nonresponders, as well as participants who switched their concomitant ART prior to the visit of interest as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA measurment (within window) for the timepoint of interest while the participant was on-treatment.
| Participants | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Week 24 | 307 | 287 |
| Week 48 | 278 | 257 |
Blood samples were collected at specified time points to assess CD4+ using flow cytometry. Median and interquartile range are presented. Baseline was the latest pre-dose assessment value (Day 1).
| Cells per cubic millimeter | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Baseline (Day 1), n=354, 361 | 204.5 (88 to 368) | 193.0 (96 to 365) |
| Week 4, n=341, 351 | 266.0 (164 to 416) | 253.0 (153 to 425) |
| Week 8, n=338, 346 | 280.0 (179 to 423) | 268.0 (163 to 445) |
| Week 12, n=335, 345 | 296.0 (188 to 451) | 289.0 (174 to 443) |
| Week 16, n=327, 338 | 299.0 (179 to 462) | 293.0 (186 to 460) |
| Week 24, n=326, 326 | 334.5 (201 to 488) | 326.5 (198 to 473) |
| Week 32, n=309, 309 | 332.0 (229 to 482) | 338.0 (215 to 484) |
| Week 40, n=299, 292 | 376.0 (239 to 523) | 349.0 (227 to 500) |
| Week 48, n=298, 286 | 387.0 (247 to 565) | 378.5 (247 to 521) |
| Week 96, n=260, 22 | 436.5 (300 to 616) | 484.5 (393 to 573) |
| Week 144, n=192, 18 | 500.0 (346 to 657) | 535.0 (371 to 579) |
Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline was the latest pre-dose assessment value (Day 1). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Median and interquartile range is presented.
| Cells per cubic millimeter | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Week 4, n=341, 351 | 53.0 (0 to 109) | 45.0 (5 to 99) |
| Week 8, n=338, 346 | 60.5 (15 to 117) | 59.0 (12 to 124) |
| Week 12, n=335, 345 | 74.0 (25 to 135) | 75.0 (22 to 141) |
| Week 16, n=327, 338 | 76.0 (20 to 156) | 79.5 (28 to 158) |
| Week 24, n=326, 326 | 99.0 (34 to 184) | 93.0 (46 to 166) |
| Week 32, n=309, 309 | 107.0 (49 to 188) | 116.0 (52 to 173) |
| Week 40, n=299, 292 | 125.0 (57 to 212) | 117.5 (51.5 to 192) |
| Week 48, n=298, 286 | 144.0 (73 to 239) | 137.0 (65 to 222) |
| Week 96, n=260, 22 | 198.5 (92.5 to 299.5) | 270 (209 to 348) |
| Week 144, n= 192, 18 | 243.0 (138 to 357) | 302.5 (154 to 390) |
Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of following conditions (CON), without any CON listed in Categories B and C: Asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: Symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C:Clinical CON listed in acquired immunodeficiency syndrome (AIDS) surveillance case definition. Indicators of CDP defined as:CDC CAT A at Baseline (BS) to CDC CAT C event (EV); CDC CAT B at BS to CDC CAT C EV; CDC CAT C at BS to new CDC CAT C EV; or CDC CAT A, B, or C at BS to death.
| Participants | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Any CAT | 32 | 25 |
| CAT B | 16 | 14 |
| CAT C | 12 | 8 |
| Death | 6 | 4 |
| Progression from CAT A to CAT C | 2 | 1 |
| Progression from CAT B to CAT C | 0 | 1 |
| Progression from CAT C to New CAT C | 9 | 5 |
| Progression from CAT A, B, or C to Death | 6 | 4 |
All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Higher the grade, more severe the symptoms.
| Participants | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| ALT | 47 | 46 |
| Albumin | 4 | 3 |
| ALP | 27 | 42 |
| AST | 49 | 52 |
| CO2 content/bicarbonate | 97 | 109 |
| Cholesterol | 99 | 103 |
| CK | 28 | 29 |
| Creatinine | 18 | 13 |
| Hyperglycaemia | 71 | 80 |
| Hyperkalemia | 7 | 6 |
| Hypernatremia | 5 | 7 |
| Hypoglycaemia | 21 | 14 |
| Hypokalemia | 37 | 41 |
| Hyponatremia | 76 | 79 |
| LDL cholesterol calculation | 68 | 82 |
| Lipase | 63 | 68 |
| Total bilirubin | 56 | 53 |
| Triglycerides | 14 | 24 |
| Hemoglobin | 19 | 27 |
| Platelet count | 36 | 32 |
| Total neutrophils | 49 | 49 |
| White Blood Cell count | 19 | 29 |
Blood samples were collected for the analysis of clinical chemistry and hematology parameters: Alanine aminotransferase (ALT), albumin, alkaline phosphate (ALP), aspartate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hypoonatremia, LDL cholesterol, lipase, total bilirubin, triglycerides, hemoglibin, neutrophils, platelets, white blood cells. Any abnormality in clinical chemistry and hematology parameters were evaluated according to the DAIDS toxicity scale From Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).Higher the grade, more severe the symptoms.
| Participants | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| ALT, Grades 1 to 4 | 36 | 9 |
| ALT, Grades 2 to 4 | 11 | 3 |
| ALT, Grades 3 to 4 | 4 | 0 |
| Albumin, Grades 1 to 4 | 3 | 0 |
| Albumin, Grades 2 to 4 | 3 | 0 |
| Albumin, Grades 3 to 4 | 0 | 0 |
| ALP, Grades 1 to 4 | 20 | 1 |
| ALP, Grades 2 to 4 | 4 | 1 |
| ALP, Grades 3 to 4 | 1 | 1 |
| AST, Grades 1 to 4 | 36 | 8 |
| AST, Grades 2 to 4 | 14 | 0 |
| AST, Grades 3 to 4 | 1 | 0 |
| CO2 content/bicarbonate, Grades 1 to 4 | 100 | 21 |
| CO2 content/bicarbonate, Grades 2 to 4 | 12 | 3 |
| CO2 content/bicarbonate, Grades 3 to 4 | 0 | 0 |
| Cholesterol, Grades 1 to 4 | 138 | 26 |
| Cholesterol, Grades 2 to 4 | 66 | 16 |
| Cholesterol, Grades 3 to 4 | 11 | 3 |
| CK, Grades 1 to 4 | 35 | 4 |
| CK, Grades 2 to 4 | 11 | 1 |
| CK, Grades 3 to 4 | 2 | 1 |
| Creatinine, Grades 1 to 4 | 20 | 2 |
| Creatinine, Grades 2 to 4 | 8 | 2 |
| Creatinine, Grades 3 to 4 | 2 | 1 |
| Hyperglycemia, Grades 1 to 4 | 94 | 10 |
| Hyperglycemia, Grades 2 to 4 | 40 | 6 |
| Hyperglycemia, Grades 3 to 4 | 7 | 1 |
| Hyperkalemia, Grades 1 to 4 | 9 | 1 |
| Hyperkalemia, Grades 2 to 4 | 4 | 1 |
| Hyperkalemia, Grades 3 to 4 | 2 | 0 |
| Hypernatremia, Grades 1 to 4 | 7 | 1 |
| Hypernatremia, Grades 2 to 4 | 1 | 0 |
| Hypernatremia, Grades 3 to 4 | 0 | 0 |
| Hypoglycemia, Grades 1 to 4 | 22 | 4 |
| Hypoglycemia, Grades 2 to 4 | 2 | 1 |
| Hypoglycemia, Grades 3 to 4 | 0 | 0 |
| Hypokalemia, Grades 1 to 4 | 29 | 13 |
| Hypokalemia, Grades 2 to 4 | 1 | 1 |
| Hypokalemia, Grades 3 to 4 | 0 | 0 |
| Hyponatremia, Grades 1 to 4 | 55 | 15 |
| Hyponatremia, Grades 2 to 4 | 2 | 0 |
| Hyponatremia, Grades 3 to 4 | 0 | 0 |
| LDL cholesterol, Grades 1 to 4 | 107 | 22 |
| LDL cholesterol, Grades 2 to 4 | 46 | 10 |
| LDL cholesterol, Grades 3 to 4 | 15 | 3 |
| Lipase, Grades 1 to 4 | 67 | 7 |
| Lipase, Grades 2 to 4 | 35 | 3 |
| Lipase, Grades 3 to 4 | 12 | 0 |
| Total bilirubin, Grades 1 to 4 | 52 | 11 |
| Total bilirubin, Grades 2 to 4 | 42 | 10 |
| Total bilirubin, Grades 3 to 4 | 18 | 6 |
| Triglycerides, Grades 1 to 4 | 23 | 2 |
| Triglycerides, Grades 2 to 4 | 23 | 2 |
| Triglycerides, Grades 3 to 4 | 11 | 1 |
| Hemoglobin, Grades 1 to 4 | 11 | 6 |
| Hemoglobin, Grades 2 to 4 | 6 | 0 |
| Hemoglobin, Grades 3 to 4 | 2 | 0 |
| Neutrophils, Grades 1 to 4 | 37 | 9 |
| Neutrophils, Grades 2 to 4 | 14 | 4 |
| Neutrophils, Grades 3 to 4 | 7 | 2 |
| Platelets, Grades 1 to 4 | 22 | 7 |
| Platelets, Grades 2 to 4 | 11 | 1 |
| Platelets, Grades 3 to 4 | 4 | 0 |
| White Blood Cells, Grades 1 to 4 | 17 | 3 |
| White Blood Cells, Grades 2 to 4 | 7 | 1 |
| White Blood Cells, Grades 3 to 4 | 0 | 0 |
Cmax, Cmin and C0_avg were assessed by population pharmacokinetic (PK) modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48. Cmax, Cmin and C0_avg were estimated and reported here.
| microgram/milliliter (µg/mL) | DTG 50 mg OD |
|---|---|
| C0_avg, n=342 | 0.926 ± 131 |
| Cmax, n=340 | 3.21 ± 26.7 |
| Cmin, n=340 | 0.849 ± 76.5 |
C0 was assessed by population PK modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48. DTG predose concentration (C0) at Week 4, Week 24, and Week 48 was estimated and reported here.
| microgram/milliliter (µg/mL) | DTG 50 mg OD |
|---|---|
| Week 4, n=329 | 0.786 ± 143 |
| Week 24, n=298 | 0.940 ± 132 |
| Week 48, n=276 | 0.932 ± 152 |
AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. AUC was assessed by population pharmacokinetic (PK) modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48.
| Micrograms*hour/milliliter (µg*hr/mL) | DTG 50 mg OD |
|---|---|
| DTG PK Parameters Including Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau Over a Dosing Interval at Steady State (AUC[0-tau]) | 44.7 ± 40.5 |
The EQ-5D-3L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 3 levels for each dimension including 1=no problems, 2=some problems, 3=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-3L utility score ranges from -0.594 to 1. Higher scores indicate better health. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value.
| Scores on a scale | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Week 24, n=350, 356 | 0.010 ± 0.202 | 0.019 ± 0.204 |
| Week 48, n=350, 356 | 0.028 ± 0.179 | 0.013 ± 0.222 |
The EQ-5D-3L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 3 levels for each dimension including 1=no problems, 2=some problems, 3=extreme problems. EQ-5D-3L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Participants were asked to rate their current health status using the visual analogue scale 'Thermometer'. Score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better heath. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value.
| Scores on a scale | DTG 50 mg OD | RAL 400 mg BID |
|---|---|---|
| Week 24, n=350, 355 | 6.800 ± 21.413 | 4.645 ± 18.279 |
| Week 48, n=350, 355 | 8.894 ± 20.356 | 5.597 ± 18.821 |
The absolute value data for CD8+ cell count was planned to be evaluated. The results for this outcome measure will never be posted.
No measurements were reported for this outcome.
Change from Baseline data for CD8+ cell count was planned to be evaluated. The results for this outcome measure will never be posted.
No measurements were reported for this outcome.
Collected over Serious adverse events (SAEs), non-serious AEs and all-cause mortality were collected from the start of study medication to the end of the study (up to Week 480). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DTG~50mg QD | 6/357 (1.7%) | 73/357 (20.4%) | 250/357 (70%) |
| RAL~400mg BID | 4/362 (1.1%) | 46/362 (12.7%) | 206/362 (56.9%) |
| Event | DTG~50mg QD | RAL~400mg BID |
|---|---|---|
| PneumoniaInfections and infestations | 7/357 | 7/362 |
| Suicidal ideationPsychiatric disorders | 4/357 | 1/362 |
| Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/357 | 0/362 |
| Acute kidney injuryRenal and urinary disorders | 3/357 | 1/362 |
| Alcohol withdrawal syndromePsychiatric disorders | 2/357 | 0/362 |
| DepressionPsychiatric disorders | 2/357 | 0/362 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 2/357 | 0/362 |
| Suicide attemptPsychiatric disorders | 2/357 | 0/362 |
| Angina pectorisCardiac disorders | 2/357 | 0/362 |
| Lower respiratory tract infectionInfections and infestations | 2/357 | 0/362 |
| Event | DTG~50mg QD | RAL~400mg BID |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 92/357 | 64/362 |
| Upper respiratory tract infectionInfections and infestations | 72/357 | 37/362 |
| CoughRespiratory, thoracic and mediastinal disorders | 46/357 | 26/362 |
| HeadacheNervous system disorders | 43/357 | 36/362 |
| NasopharyngitisInfections and infestations | 43/357 | 22/362 |
| InfluenzaInfections and infestations | 42/357 | 34/362 |
| HypertensionVascular disorders | 39/357 | 15/362 |
| NauseaGastrointestinal disorders | 35/357 | 31/362 |
| Urinary tract infectionInfections and infestations | 35/357 | 20/362 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 34/357 | 27/362 |
Four participants from one closed site were removed from the ITT-E Population creating the modified ITT-E Population with 715 participants.
| Age, Continuous(Years) | DTG 50 mg OD | RAL 400 mg BID | Total |
|---|---|---|---|
| Mean | 42.6 ± 10.45 | 42.5 ± 9.81 | 42.5 ± 10.13 |
| Sex: Female, Male(Participants) | DTG 50 mg OD | RAL 400 mg BID | Total |
|---|---|---|---|
| Female | 107 | 123 | 230 |
| Male | 247 | 238 | 485 |
| Race/Ethnicity, Customized(Participants) | DTG 50 mg OD | RAL 400 mg BID | Total |
|---|---|---|---|
| African American/African Heritage | 143 | 160 | 303 |
| American Indian or Alaska Native | 10 | 17 | 27 |
| Asian-Central/South Asian Heritage | 2 | 2 | 4 |
| Asian-East Asian Heritage | 6 | 4 | 10 |
| Asian-South East Asian Heritage | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White-Arabic/North African Heritage | 3 | 3 | 6 |
| White-White/Caucasian/European Heritage | 175 | 172 | 347 |
| Mixed Race | 12 | 2 | 14 |
| Unknown | 1 | 1 | 2 |
Showing the first 100 of 181 sites across 20 countries. Choose a country and city above to see the rest.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Oct 2010 to primary completion in Feb 2013, 27 months.
Results were first posted in Jan 2014, 11 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 27 months is above that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir